GlassScriptPhysician profile
Michael Joseph Demeure
NPI 1629041579
$52,727.74
in general payments reported to CMS, 2019-2025
18 companies · $4,353 in 2025
The $4,353 reported for 2025 was more than what 89% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,416 · 2020: $4,809 · 2021: $8,050 · 2022: $10K · 2023: $18K · 2024: $5,245 · 2025: $4,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,458 · Food and Beverage: $1,046 · Travel and Lodging: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,775.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,458.00 |
| Food and Beverage | $1,045.69 |
| Travel and Lodging | $891.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $26,950.00 | 2020-2023 | |
| Corcept Therapeutics | $8,945.63 | 2024-2025 | Korlym |
| Aadi Bioscience, INC. | $5,838.68 | 2023-2025 | Fyarro |
| Array Biopharma INC | $4,200.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,060.00 | 2022 | |
| Exelixis INC. | $2,237.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $948.30 | 2020-2022 | |
| Covidien LP | $162.18 | 2019 | |
| Roche Diagnostics Corporation | $135.50 | 2023 | |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Baxter Healthcare | $35.84 | 2023 | Perclot |
| Acell, INC. | $30.69 | 2020 | |
| Foundation Medicine, INC. | $27.82 | 2020 | |
| Abbvie INC. | $16.63 | 2019 | |
| Caris Mpi, INC. | $16.22 | 2025 | Mi Cancer Seek |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $14.01 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Demeure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.